Investigating the role of IgE antibodies to a specific sugar in heart disease
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis
This study is looking at how certain antibodies related to tick bites might affect heart health, specifically how they could be linked to the buildup of plaque in the arteries, and it's for anyone interested in understanding more about heart disease and its prevention.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10852001 on NIH RePORTER |
What this research studies
This research explores how IgE antibodies to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) may influence the development of coronary artery disease (CAD). It examines the relationship between IgE sensitization to alpha-gal, which can occur after tick bites, and the formation of atherosclerotic plaques in the arteries. By analyzing blood samples and immune responses, the study aims to uncover the mechanisms by which these antibodies may contribute to heart disease, potentially leading to new insights into prevention and treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of tick bites and elevated IgE levels, particularly those who consume alpha-gal-containing foods.
Not a fit: Patients without IgE sensitization to alpha-gal or those who do not have coronary artery disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating coronary artery disease in individuals sensitized to alpha-gal.
How similar studies have performed: While the specific role of IgE to alpha-gal in CAD is not extensively studied, related research has shown associations between IgE levels and cardiovascular conditions, indicating potential for impactful findings.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Erickson, Loren D — University of Virginia
- Study coordinator: Erickson, Loren D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.